Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin

R. S. Kidd, Timothy B Curry, S. Gallagher, T. Edeki, J. Blaisdell, J. A. Goldstein

Research output: Contribution to journalArticle

230 Citations (Scopus)

Abstract

Cytochrome P450 (CYP) 2C9 is the principal enzyme responsible for the metabolism of numerous clinically important drugs. Two polymorphic alleles CYP2C9*2 and CYP2C9z.ast;3 have been documented which affect the metabolism and clinical toxicity of drugs such as phenytoin, warfarin, glipizide, and tolbutamide. The present study reports the first example of a null polymorphism in CYP2C9. This mutation dramatically affects the half-life and clinical toxicity of phenytoin. The study subject was a female African-American presented to the emergency department with phenytoin toxicity evidenced by mental confusion, slurred speech, memory loss and the inability to stand. She exhibited extremely poor clearance of phenytoin with an elimination half-life of approximately 13 days. Genotyping studies demonstrated that the patient did not possess any known variant CYP2C9 alleles. Phenytoin is metabolized to a minor extent by the polymorphic CYP2C19, but this individual did not possess any variant CYP2C19 alleles, Sequencing studies revealed that the individual was homozygous for a new CYP2C9 allele (CYP2C9*6) with the deletion of an adenine at base pair 818 of the cDNA. The clearance of phenytoin in this individual is estimated to be approximately 17% of that observed in normal patients. The frequency of this allele was 0.6% (95% confidence limits of 0.1 to 3.5%) in 79 African-Americans and 0% (95% confidence limits of 0 to 1.1%) in 172 Caucasians. The study also demonstrates the severe clinical consequences to patients with a null mutation in CYP2C9 after treatment with normal doses of phenytoin.

Original languageEnglish (US)
Pages (from-to)803-808
Number of pages6
JournalPharmacogenetics
Volume11
Issue number9
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Phenytoin
African Americans
Alleles
Half-Life
Glipizide
Confusion
Tolbutamide
Mutation
Memory Disorders
Adenine
Warfarin
Cytochrome P-450 CYP2C9
Drug-Related Side Effects and Adverse Reactions
Gene Frequency
Base Pairing
Cytochrome P-450 Enzyme System
Hospital Emergency Service
Complementary DNA
Enzymes
Pharmaceutical Preparations

Keywords

  • Cytochrome P450
  • Pharmacokinetics
  • Phenytoin
  • Polymorphism

ASJC Scopus subject areas

  • Genetics
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. / Kidd, R. S.; Curry, Timothy B; Gallagher, S.; Edeki, T.; Blaisdell, J.; Goldstein, J. A.

In: Pharmacogenetics, Vol. 11, No. 9, 2001, p. 803-808.

Research output: Contribution to journalArticle

Kidd, R. S. ; Curry, Timothy B ; Gallagher, S. ; Edeki, T. ; Blaisdell, J. ; Goldstein, J. A. / Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. In: Pharmacogenetics. 2001 ; Vol. 11, No. 9. pp. 803-808.
@article{4c10b76971064d9e97cc39c8beadd47e,
title = "Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin",
abstract = "Cytochrome P450 (CYP) 2C9 is the principal enzyme responsible for the metabolism of numerous clinically important drugs. Two polymorphic alleles CYP2C9*2 and CYP2C9z.ast;3 have been documented which affect the metabolism and clinical toxicity of drugs such as phenytoin, warfarin, glipizide, and tolbutamide. The present study reports the first example of a null polymorphism in CYP2C9. This mutation dramatically affects the half-life and clinical toxicity of phenytoin. The study subject was a female African-American presented to the emergency department with phenytoin toxicity evidenced by mental confusion, slurred speech, memory loss and the inability to stand. She exhibited extremely poor clearance of phenytoin with an elimination half-life of approximately 13 days. Genotyping studies demonstrated that the patient did not possess any known variant CYP2C9 alleles. Phenytoin is metabolized to a minor extent by the polymorphic CYP2C19, but this individual did not possess any variant CYP2C19 alleles, Sequencing studies revealed that the individual was homozygous for a new CYP2C9 allele (CYP2C9*6) with the deletion of an adenine at base pair 818 of the cDNA. The clearance of phenytoin in this individual is estimated to be approximately 17{\%} of that observed in normal patients. The frequency of this allele was 0.6{\%} (95{\%} confidence limits of 0.1 to 3.5{\%}) in 79 African-Americans and 0{\%} (95{\%} confidence limits of 0 to 1.1{\%}) in 172 Caucasians. The study also demonstrates the severe clinical consequences to patients with a null mutation in CYP2C9 after treatment with normal doses of phenytoin.",
keywords = "Cytochrome P450, Pharmacokinetics, Phenytoin, Polymorphism",
author = "Kidd, {R. S.} and Curry, {Timothy B} and S. Gallagher and T. Edeki and J. Blaisdell and Goldstein, {J. A.}",
year = "2001",
doi = "10.1097/00008571-200112000-00008",
language = "English (US)",
volume = "11",
pages = "803--808",
journal = "Pharmacogenetics and Genomics",
issn = "1744-6872",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin

AU - Kidd, R. S.

AU - Curry, Timothy B

AU - Gallagher, S.

AU - Edeki, T.

AU - Blaisdell, J.

AU - Goldstein, J. A.

PY - 2001

Y1 - 2001

N2 - Cytochrome P450 (CYP) 2C9 is the principal enzyme responsible for the metabolism of numerous clinically important drugs. Two polymorphic alleles CYP2C9*2 and CYP2C9z.ast;3 have been documented which affect the metabolism and clinical toxicity of drugs such as phenytoin, warfarin, glipizide, and tolbutamide. The present study reports the first example of a null polymorphism in CYP2C9. This mutation dramatically affects the half-life and clinical toxicity of phenytoin. The study subject was a female African-American presented to the emergency department with phenytoin toxicity evidenced by mental confusion, slurred speech, memory loss and the inability to stand. She exhibited extremely poor clearance of phenytoin with an elimination half-life of approximately 13 days. Genotyping studies demonstrated that the patient did not possess any known variant CYP2C9 alleles. Phenytoin is metabolized to a minor extent by the polymorphic CYP2C19, but this individual did not possess any variant CYP2C19 alleles, Sequencing studies revealed that the individual was homozygous for a new CYP2C9 allele (CYP2C9*6) with the deletion of an adenine at base pair 818 of the cDNA. The clearance of phenytoin in this individual is estimated to be approximately 17% of that observed in normal patients. The frequency of this allele was 0.6% (95% confidence limits of 0.1 to 3.5%) in 79 African-Americans and 0% (95% confidence limits of 0 to 1.1%) in 172 Caucasians. The study also demonstrates the severe clinical consequences to patients with a null mutation in CYP2C9 after treatment with normal doses of phenytoin.

AB - Cytochrome P450 (CYP) 2C9 is the principal enzyme responsible for the metabolism of numerous clinically important drugs. Two polymorphic alleles CYP2C9*2 and CYP2C9z.ast;3 have been documented which affect the metabolism and clinical toxicity of drugs such as phenytoin, warfarin, glipizide, and tolbutamide. The present study reports the first example of a null polymorphism in CYP2C9. This mutation dramatically affects the half-life and clinical toxicity of phenytoin. The study subject was a female African-American presented to the emergency department with phenytoin toxicity evidenced by mental confusion, slurred speech, memory loss and the inability to stand. She exhibited extremely poor clearance of phenytoin with an elimination half-life of approximately 13 days. Genotyping studies demonstrated that the patient did not possess any known variant CYP2C9 alleles. Phenytoin is metabolized to a minor extent by the polymorphic CYP2C19, but this individual did not possess any variant CYP2C19 alleles, Sequencing studies revealed that the individual was homozygous for a new CYP2C9 allele (CYP2C9*6) with the deletion of an adenine at base pair 818 of the cDNA. The clearance of phenytoin in this individual is estimated to be approximately 17% of that observed in normal patients. The frequency of this allele was 0.6% (95% confidence limits of 0.1 to 3.5%) in 79 African-Americans and 0% (95% confidence limits of 0 to 1.1%) in 172 Caucasians. The study also demonstrates the severe clinical consequences to patients with a null mutation in CYP2C9 after treatment with normal doses of phenytoin.

KW - Cytochrome P450

KW - Pharmacokinetics

KW - Phenytoin

KW - Polymorphism

UR - http://www.scopus.com/inward/record.url?scp=0035217171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035217171&partnerID=8YFLogxK

U2 - 10.1097/00008571-200112000-00008

DO - 10.1097/00008571-200112000-00008

M3 - Article

C2 - 11740344

AN - SCOPUS:0035217171

VL - 11

SP - 803

EP - 808

JO - Pharmacogenetics and Genomics

JF - Pharmacogenetics and Genomics

SN - 1744-6872

IS - 9

ER -